Study on long-term safety of mexiletine for myotonic dystrophy
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study tests if a daily capsule of mexiletine is safe and helpful over 26 weeks for people with myotonic dystrophy type 1 or 2. It's for people who finished a previous related study and want to continue treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have myotonic dystrophy type 1 or 2 confirmed by a genetic test.
- You are at least 16 years old and not pregnant.
- You have a body mass index (BMI) between 18.5 and 30 and weigh at least 45 kg.
- You have enough hand strength to grip a device that measures muscle stiffness.
- Your heart is healthy based on a cardiologist's check, including an EKG and other tests.
- You are not taking certain heart medications or drugs that might interfere with mexiletine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a once-daily drug called mexiletine PR to see if it can help reduce muscle stiffness (myotonia) in people with myotonic dystrophy type 1 or 2. It may be a good option if you have a confirmed genetic diagnosis and are at least 16 years old.
This study is a long-term follow-up for people with myotonic dystrophy type 1. It aims to find better ways to measure how the disease progresses, which could help develop future treatments.
This study uses MRI scans to measure muscle changes in people with myotonic dystrophy (DM1 or DM2) and healthy volunteers. The goal is to find better ways to track the disease over time.
This study looks at how to best measure muscle health and function in children with myotonic dystrophy. It may help prepare for future treatment trials.
This trial compares a new extended-release (PR) form of mexiletine to the immediate-release (IR) form in people with non-dystrophic myotonias. The goal is to see if the longer-acting version works as well or better with fewer side effects.
This study follows children under 6 years old with genetic myotonic disorders who are taking or may take mexiletine. It helps doctors understand how well the medicine works and if it is safe over time.
Hear when a new Myotonic Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.